sibutramine has been researched along with Diabetes Mellitus in 21 studies
sibutramine: serotonin and norepinephrine transporter inhibitor; Meridia is tradename for sibutramine hydrochloride
Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Weight loss induced by sibutramine, diet, and exercise attenuates falls in blood glucose levels and HbA1c compared with similar weight loss with placebo, diet, and exercise." | 9.24 | Influence of sibutramine in addition to diet and exercise on the relationship between weight loss and blood glucose changes. ( Andersson, C; Caterson, ID; Finer, N; James, WPT; Kamil, S; Torp-Pedersen, C, 2017) |
| "The results of this study confirm that sibutramine, orlistat and metformin are all effective and safe medications that reduce cardiovascular risk and can decrease the risk of type 2 diabetes mellitus in obese females." | 9.10 | Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. ( BascilTutuncu, N; Gokcel, A; Gumurdulu, Y; Guvener, N; Karakose, H; Melek Ertorer, E; Tanaci, N, 2002) |
| "Sibutramine produced statistically and clinically significant weight loss when used in combination with recommendations for moderate caloric restriction." | 9.09 | Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. ( Fujioka, K; Jelinek, CA; Lebovitz, HE; Raskin, P; Rowe, E; Seaton, TB; Weinstein, SP, 2000) |
| " After failure of lifestyle modifications, antiobesity drugs such as orlistat, a potent and selective inhibitor of gastric and pancreatic lipases that reduces lipid intestinal absorption, or sibutramine, a noradrenaline and 5-hydroxytryptamine reuptake inhibitor that regulates food intake, may be considered to favour weight loss and/or weight maintenance." | 8.81 | New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat. ( Ernest, P; Scheen, AJ, 2002) |
| "Sibutramine treatment decreased body weight gain by 12% without a significant overall change in daily food intake." | 7.70 | Effect of the antiobesity agent sibutramine in obese-diabetic ob/ob mice. ( Bailey, CJ; Day, C, 1998) |
| "Weight loss induced by sibutramine, diet, and exercise attenuates falls in blood glucose levels and HbA1c compared with similar weight loss with placebo, diet, and exercise." | 5.24 | Influence of sibutramine in addition to diet and exercise on the relationship between weight loss and blood glucose changes. ( Andersson, C; Caterson, ID; Finer, N; James, WPT; Kamil, S; Torp-Pedersen, C, 2017) |
| "The mean weight loss was greater in the sibutramine group (-7." | 5.11 | Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes. ( Kaukua, JK; Pekkarinen, TA; Rissanen, AM, 2004) |
| "Sibutramine, in conjunction with moderate caloric restriction, enhances weight loss and reduces waist circumference in overweight and obese Type 2 diabetic patients receiving sulphonylurea therapy." | 5.10 | Role of sibutramine in the treatment of obese Type 2 diabetic patients receiving sulphonylurea therapy. ( Melchionda, N; Moreno-Carretero, E; Serrano-Rios, M, 2002) |
| "The results of this study confirm that sibutramine, orlistat and metformin are all effective and safe medications that reduce cardiovascular risk and can decrease the risk of type 2 diabetes mellitus in obese females." | 5.10 | Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. ( BascilTutuncu, N; Gokcel, A; Gumurdulu, Y; Guvener, N; Karakose, H; Melek Ertorer, E; Tanaci, N, 2002) |
| "Sibutramine produced statistically and clinically significant weight loss when used in combination with recommendations for moderate caloric restriction." | 5.09 | Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. ( Fujioka, K; Jelinek, CA; Lebovitz, HE; Raskin, P; Rowe, E; Seaton, TB; Weinstein, SP, 2000) |
| "The addition of sibutramine to oral hypoglycemic therapy resulted in significant weight loss and improvement in metabolic parameters in this patient group." | 5.09 | Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. ( Ertorer, EM; Gokcel, A; Guvener, N; Karakose, H; Tanaci, N; Tutuncu, NB, 2001) |
| " Food and Drug Administration has approved three weight loss agents: sibutramine, orlistat, and phentermine." | 4.83 | Use of lifestyle changes treatment plans and drug therapy in controlling cardiovascular and metabolic risk factors. ( Pi-Sunyer, FX, 2006) |
| " The two available drugs, orlistat and sibutramine, are capable of reducing body weight by 10%." | 4.82 | [Pharmacotherapy of obesity]. ( Ludvik, B; Tripp, B, 2004) |
| "Sibutramine-induced weight loss and weight maintenance lead to clinically relevant reductions in risk factors associated with the metabolic syndrome." | 4.81 | Metabolic benefits associated with sibutramine therapy. ( Krejs, GJ, 2002) |
| " After failure of lifestyle modifications, antiobesity drugs such as orlistat, a potent and selective inhibitor of gastric and pancreatic lipases that reduces lipid intestinal absorption, or sibutramine, a noradrenaline and 5-hydroxytryptamine reuptake inhibitor that regulates food intake, may be considered to favour weight loss and/or weight maintenance." | 4.81 | New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat. ( Ernest, P; Scheen, AJ, 2002) |
| "Sibutramine treatment decreased body weight gain by 12% without a significant overall change in daily food intake." | 3.70 | Effect of the antiobesity agent sibutramine in obese-diabetic ob/ob mice. ( Bailey, CJ; Day, C, 1998) |
| "A total of 195 subjects (44% male) with type 2 diabetes and a BMI >27 kg/m(2) were studied." | 2.71 | A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. ( McNulty, SJ; Ur, E; Williams, G, 2003) |
| "Obesity is a major risk factor for the development of type 2 diabetes and is an important obstacle to the management of this disease." | 2.40 | Obesity and type 2 diabetes: a conflict of interests? ( Williams, G, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (9.52) | 18.2507 |
| 2000's | 16 (76.19) | 29.6817 |
| 2010's | 3 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kamil, S | 1 |
| Finer, N | 1 |
| James, WPT | 1 |
| Caterson, ID | 1 |
| Andersson, C | 1 |
| Torp-Pedersen, C | 1 |
| Hemo, B | 1 |
| Endevelt, R | 1 |
| Porath, A | 1 |
| Stampfer, MJ | 1 |
| Shai, I | 1 |
| Kautzky-Willer, A | 1 |
| Lemmens-Gruber, R | 1 |
| Matiba, B | 1 |
| Krejs, GJ | 1 |
| McNulty, SJ | 1 |
| Ur, E | 1 |
| Williams, G | 2 |
| Scheen, AJ | 1 |
| Ernest, P | 1 |
| Hauner, H | 1 |
| Connor, H | 1 |
| Annan, F | 1 |
| Bunn, E | 1 |
| Frost, G | 1 |
| McGough, N | 1 |
| Sarwar, T | 1 |
| Thomas, B | 1 |
| Kaukua, JK | 1 |
| Pekkarinen, TA | 1 |
| Rissanen, AM | 1 |
| Tripp, B | 1 |
| Ludvik, B | 1 |
| Patel, MR | 1 |
| Donahue, M | 1 |
| Wilson, PW | 1 |
| Califf, RM | 1 |
| Pi-Sunyer, FX | 1 |
| Ara, R | 1 |
| Brennan, A | 1 |
| Day, C | 1 |
| Bailey, CJ | 1 |
| Fujioka, K | 1 |
| Seaton, TB | 1 |
| Rowe, E | 1 |
| Jelinek, CA | 1 |
| Raskin, P | 1 |
| Lebovitz, HE | 1 |
| Weinstein, SP | 1 |
| Gokcel, A | 2 |
| Karakose, H | 2 |
| Ertorer, EM | 1 |
| Tanaci, N | 2 |
| Tutuncu, NB | 1 |
| Guvener, N | 2 |
| Serrano-Rios, M | 1 |
| Melchionda, N | 1 |
| Moreno-Carretero, E | 1 |
| Gumurdulu, Y | 1 |
| Melek Ertorer, E | 1 |
| BascilTutuncu, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double-blind, Randomized Clinical Trial to Evaluate Effect of Combination Therapy of Metformin and Sibutramine Versus Metformin or Sibutramine Monotherapy Over Weight, Adiposity, Glucose Metabolism and Inflammatory State in Obese Patients[NCT00941382] | Phase 3 | 60 participants (Anticipated) | Interventional | 2008-11-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for sibutramine and Diabetes Mellitus
| Article | Year |
|---|---|
Obesity and diabetes.
Topics: Animals; Cyclobutanes; Diabetes Mellitus; Female; Humans; Incretins; Insulin; Lactones; Male; Metfor | 2012 |
Metabolic benefits associated with sibutramine therapy.
Topics: Adipose Tissue; Appetite Depressants; Cyclobutanes; Diabetes Mellitus; Humans; Lipids; Obesity; Weig | 2002 |
New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat.
Topics: Anti-Obesity Agents; Appetite Depressants; Blood Glucose; Clinical Trials as Topic; Controlled Clini | 2002 |
[Pharmacotherapy of obesity].
Topics: Appetite Depressants; Body Weight; Clinical Trials as Topic; Cyclobutanes; Diabetes Mellitus; Humans | 2004 |
Clinical trial issues in weight-loss therapy.
Topics: Anti-Obesity Agents; Behavior Therapy; Cardiovascular Diseases; Clinical Trials as Topic; Comorbidit | 2006 |
Use of lifestyle changes treatment plans and drug therapy in controlling cardiovascular and metabolic risk factors.
Topics: Caloric Restriction; Cardiovascular Diseases; Cyclobutanes; Diabetes Mellitus; Diet; Diet, Fat-Restr | 2006 |
Obesity and type 2 diabetes: a conflict of interests?
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diabetes Complications; Diabetes Mellitus; | 1999 |
8 trials available for sibutramine and Diabetes Mellitus
| Article | Year |
|---|---|
Influence of sibutramine in addition to diet and exercise on the relationship between weight loss and blood glucose changes.
Topics: Appetite Depressants; Blood Glucose; Cyclobutanes; Diabetes Mellitus; Diet; Dose-Response Relationsh | 2017 |
A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin.
Topics: Appetite Depressants; Blood Glucose; Blood Pressure; Body Weight; Cyclobutanes; Diabetes Mellitus; D | 2003 |
Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes.
Topics: Adult; Aged; Appetite Depressants; Blood Glucose; Cyclobutanes; Diabetes Complications; Diabetes Mel | 2004 |
The cost-effectiveness of sibutramine in non-diabetic obese patients: evidence from four Western countries.
Topics: Adult; Age Distribution; Aged; Appetite Depressants; Cohort Studies; Coronary Disease; Cost-Benefit | 2007 |
Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus.
Topics: Adolescent; Adult; Aged; Appetite Depressants; Blood Pressure; Body Mass Index; Cyclobutanes; Diabet | 2000 |
Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control.
Topics: Appetite Depressants; Blood Glucose; Cholesterol; Cyclobutanes; Diabetes Mellitus; Double-Blind Meth | 2001 |
Role of sibutramine in the treatment of obese Type 2 diabetic patients receiving sulphonylurea therapy.
Topics: Appetite Depressants; Body Mass Index; Body Weight; Cholesterol; Cyclobutanes; Diabetes Mellitus; Di | 2002 |
Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Blood Glucose; Body Mass Index; Body Weight; Cyclo | 2002 |
6 other studies available for sibutramine and Diabetes Mellitus
| Article | Year |
|---|---|
Adherence to weight loss medications; post-marketing study from HMO pharmacy data of one million individuals.
Topics: Adult; Analysis of Variance; Anti-Obesity Agents; Body Mass Index; Comorbidity; Cyclobutanes; Diabet | 2011 |
[The anti-obesity drug sibutramine for overweight diabetic patients. "Blood pressure is not elevated")].
Topics: Appetite Depressants; Blood Pressure; Cyclobutanes; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hu | 2002 |
[Weight loss lowers blood pressure, lipids and blood glucose. Sibutramine also helps diabetics with weight loss].
Topics: Appetite Depressants; Blood Glucose; Blood Pressure; Cyclobutanes; Diabetes Mellitus; Diabetes Melli | 2002 |
[A drug help in reducing? Risk profile decides whether and how].
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Blood Glucose; Body Mass Index; Cyclobutanes; Diab | 2003 |
The implementation of nutritional advice for people with diabetes.
Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Asian People; Body Composition; Child; Cyclobutanes; D | 2003 |
Effect of the antiobesity agent sibutramine in obese-diabetic ob/ob mice.
Topics: Animals; Appetite Depressants; Blood Glucose; Cyclobutanes; Diabetes Mellitus; Fatty Acids, Nonester | 1998 |